Bryce Point Capital’s Arcellx ACLX Stock Holding History

Bryce Point Capital’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,475	Closed	-$573K	–	179
2024 Q4	$573K	Buy	+7,475	New	+$646K	0.17%	173

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Bryce Point Capital's ACLX Position: Q1 2025 in Review

Bryce Point Capital sold out of Arcellx (ACLX) in Q1 2025, closing a stake of 7,475 shares — an estimated $573K sold.

Bryce Point Capital first reported a position in ACLX in Q4 2024 and held it in 1 quarter. The position peaked at $573K in Q4 2024. 197 funds tracked by Wall St. Rank hold ACLX as of Q1 2025.

Bryce Point Capital reported no remaining Arcellx position as of Q1 2025 after selling out during the quarter.
Bryce Point Capital sold 7,475 Arcellx shares in Q1 2025, an estimated $573K.
Bryce Point Capital first reported a position in Arcellx in Q4 2024 and held it in 1 quarter.
Bryce Point Capital's Arcellx position peaked at $573K in Q4 2024.
197 funds tracked by Wall St. Rank held Arcellx as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.